Biolife Sciences (BLFE) Ratios
Biolife Sciences Ratios
BLFE's free cash flow for Q1 2022 was $-2.00. For the 2022 fiscal year, BLFE's free cash flow was increased by $0.00 and operating cash flow was $-2.00. See a summary of the company’s cash flow.
| Ratios | Nov 20 | Nov 19 | Nov 18 | Nov 17 |
|---|---|---|---|---|
| Liquidity Ratios | ||||
| Current Ratio | 0.09 | 0.01 | 0.01 | 0.10 |
| Quick Ratio | 0.09 | 0.01 | 0.01 | 0.10 |
| Cash Ratio | 0.05 | 0.01 | 0.01 | 0.10 |
| Solvency Ratio | -1.39 | 145.80 | -0.24 | -1.74 |
| Operating Cash Flow Ratio | -1.16 | 0.01 | -0.08 | -0.14 |
| Short-Term Operating Cash Flow Coverage | -4.66 | 0.00 | -0.17 | -0.25 |
| Net Current Asset Value | $ -690.57K | $ -1.15K | $ -220.87K | $ -183.10K |
| Leverage Ratios | ||||
| Debt-to-Assets Ratio | 2.61 | 0.00 | 107.72 | 11.40 |
| Debt-to-Equity Ratio | -0.27 | 0.00 | -0.64 | -0.77 |
| Debt-to-Capital Ratio | -0.38 | 0.00 | -1.81 | -3.32 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | -0.43 | -0.57 |
| Financial Leverage Ratio | -0.11 | -0.01 | -0.01 | -0.07 |
| Debt Service Coverage Ratio | -5.10 | 0.00 | -0.49 | -3.86 |
| Interest Coverage Ratio | -25.22 | 0.00 | -4.05 | -29.23 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.01 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.01 | 0.03 |
| Net Debt to EBITDA | -0.13 | -0.00 | -3.33 | -0.39 |
| Profitability Margins | ||||
| Gross Profit Margin | -239.25% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | -295.85% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | -295.95% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | -302.17% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | -307.99% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | -307.99% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | -307.99% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 101.93% | 0.00% | 124.68% | 103.34% |
| Return on Assets (ROA) | -1743.72% | -6670.59% | -3993.56% | -2755.94% |
| Return on Equity (ROE) | 183.88% | 98.27% | 23.87% | 185.69% |
| Return on Capital Employed (ROCE) | 180.40% | 0.00% | 27.42% | 282.52% |
| Return on Invested Capital (ROIC) | 248.80% | 0.00% | 53.74% | 775.89% |
| Return on Tangible Assets | -1743.72% | -6670.59% | -3993.56% | -2755.94% |
| Earnings Yield | -2.17% | -0.00% | -0.12% | -3.25% |
| Efficiency Ratios | ||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 2.83 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 415.43 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 5.66 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | -1.19 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -128.82 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 128.82 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | ||||
| Operating Cash Flow Per Share | -0.02 | 0.00 | -0.00 | -0.00 |
| Free Cash Flow Per Share | -0.02 | 0.00 | -0.00 | -0.00 |
| Dividend Paid and CapEx Coverage Ratio | -920.20 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | -920.20 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | -4.66 | 0.00 | -0.09 | -0.13 |
| Operating Cash Flow to Sales Ratio | -2.15 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -1.51% | 0.00% | -0.03% | -0.18% |
| Valuation Ratios | ||||
| Price-to-Earnings (P/E) Ratio | -46.14 | -40306.66 | -867.07 | -30.76 |
| Price-to-Sales (P/S) Ratio | 142.12 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | -84.85 | -39608.11 | -206.95 | -57.11 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -66.09 | 2688691.54 | -3651.65 | -561.30 |
| Price-to-Operating Cash Flow Ratio | -66.16 | 2688691.54 | -3651.65 | -561.30 |
| Price-to-Earnings Growth (PEG) Ratio | -0.00 | 418.57 | 8.99 | -0.45 |
| Enterprise Value Multiple | -48.15 | 265.96 | -1084.30 | -32.18 |
| Enterprise Value | 58.66M | 45.71M | 45.85M | 10.59M |
| EV to EBITDA | -48.15 | 265.96 | -1084.30 | -32.18 |
| EV to Sales | 142.49 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -66.27 | 2688690.54 | -3662.91 | -568.19 |
| EV to Operating Cash Flow | -66.34 | 2688690.54 | -3662.91 | -568.19 |
| Tangible Book Value Per Share | -0.01 | -0.00 | -0.01 | -0.04 |
| Shareholders’ Equity Per Share | -0.01 | -0.00 | -0.01 | -0.04 |
| Tax and Other Ratios | ||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.01 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.02 | -0.00 | -0.00 | -0.08 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.04 | 0.00 | 1.25 | 1.03 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.70 | -0.01 | 0.24 | 0.05 |
Currency in USD